Cancer Immunology Reserch

Inhibition of PIM kinase in tumor-associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy

by

Cancer Immunol Res. 2025 Feb 21. doi: 10.1158/2326-6066.CIR-24-0591. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm for many cancers but have not shown benefit in prostate cancer (PCa). Chronic inflammation contributes to the immunosuppressive prostate tumor microenvironment (TME) and is associated with poor response to ICIs. The primary source … Read more

PTP inhibition improves the macrophage anti-tumor immune response and the efficacy of chemo- and radiotherapy

by

Cancer Immunol Res. 2025 Feb 12. doi: 10.1158/2326-6066.CIR-24-0335. Online ahead of print. ABSTRACT Traditional anti-cancer therapies induce tumor cell death and subsequent release of Damage Associated Molecular Patterns (DAMPs) that activate the innate inflammatory response. Paradoxically, after treatment, macrophages often adopt a pro-wound healing, rather than pro-inflammatory, phenotype and contribute to cancer progression. We found … Read more

TLR5 signaling causes dendritic-cell dysfunction and orchestrates failure of immune checkpoint therapy against ovarian cancer

by

Cancer Immunol Res. 2025 Feb 11. doi: 10.1158/2326-6066.CIR-24-0513. Online ahead of print. ABSTRACT Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system. Patients who have ovarian tumors infiltrated with high frequencies of T cells are associated with a greater survival probability. However, therapies to revitalize tumor-associated T cells, such … Read more

Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500

by

Cancer Immunol Res. 2025 Feb 7. doi: 10.1158/2326-6066.CIR-24-0103. Online ahead of print. ABSTRACT The tumor microenvironment (TME) in solid tumors contains myeloid cells that modulate local immune activity. STING signaling activation in these myeloid cells enhances local type I interferon (IFN) production, inducing an innate immune response that mobilizes adaptive immunity and reprograms immunosuppressive myeloid … Read more

Tertiary lymphoid structures are associated with enhanced macrophage activation and immune checkpoint expression, and predict outcome in cervical cancer

by

Cancer Immunol Res. 2025 Jan 31. doi: 10.1158/2326-6066.CIR-24-0979. Online ahead of print. ABSTRACT Cervical tumors are usually treated using surgery, chemotherapy, and radiotherapy, and would benefit from immunotherapies. However, the immune microenvironment in cervical cancer remains poorly described. Tertiary lymphoid structures (TLS) were recently described as markers for better immunotherapy response and overall better prognosis … Read more

A bifunctional antibody targeting PD-1 and TGF-β signaling has antitumor activity in combination with radiotherapy and attenuates radiation-induced lung injury

by

Cancer Immunol Res. 2025 Jan 29. doi: 10.1158/2326-6066.CIR-23-0903. Online ahead of print. ABSTRACT Radio-immunotherapy has antitumor activity but also causes toxicity, which limits its clinical application. JS-201 is a dual antibody targeting PD-1 and TGF-β signaling. We investigated the antitumour effect of JS-201 combined with radiotherapy and the effect on radiation-induced lung injury (RILI). Different … Read more

Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer

by

Cancer Immunol Res. 2025 Jan 24. doi: 10.1158/2326-6066.CIR-24-0649. Online ahead of print. ABSTRACT Testing for PD-L1 expression by immunohistochemistry (IHC) is used to predict immune checkpoint blockade (ICB) benefit but has performed inconsistently in urothelial cancer (UC) clinical trials. Different approaches are used for PD-L1 IHC. We analyzed paired PD-L1 IHC data on UC samples … Read more

PRDM1 is a key regulator of the natural killer T-cell central memory program and effector function

by

Cancer Immunol Res. 2025 Jan 16. doi: 10.1158/2326-6066.CIR-24-0259. Online ahead of print. ABSTRACT Natural killer T cells (NKTs) are a promising platform for cancer immunotherapy, but few genes involved in regulation of NKT therapeutic activity have been identified. To find regulators of NKT functional fitness, we developed a CRISPR/Cas9-based mutagenesis screen that employs a guide … Read more

PKCδ germline variants and genetic deletion in mice augment antitumor immunity through regulation of myeloid cells

by

Cancer Immunol Res. 2025 Jan 14. doi: 10.1158/2326-6066.CIR-23-0999. Online ahead of print. ABSTRACT Based on the notion that hypomorphic germline genetic variants are linked to autoimmune diseases, we reasoned that novel targets for cancer immunotherapy might be identified through germline variants associated with greater T-cell infiltration into tumors. Here, we report that while investigating germline … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri cURL Hatası: Could not resolve host: lkl.dolarkurum.com